Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.68 |
| ▸ | SMPD3 | Q9NY59 | 8/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30102975 | 1.00 | AAK1 (0.68) | AAK1SMPD3NTRK1JAK2JAK3 | |
| SCHEMBL29660328 | 0.94 | AAK1 (0.69) | AAK1SMPD3NTRK1JAK2JAK3 | |
| SCHEMBL19466999 | 0.90 | AAK1 (0.61) | AAK1SMPD3NTRK1JAK2JAK3 | |
| SCHEMBL29660261 | 0.88 | AAK1 (0.52) | AAK1SMPD3NTRK1JAK2 | |
| SCHEMBL29660269 | 0.88 | AAK1 (0.51) | AAK1SMPD3 | |
| SCHEMBL29660251 | 0.88 | AAK1 (0.51) | AAK1SMPD3PDE10A | |
| SCHEMBL29660275 | 0.88 | AAK1 (0.51) | AAK1NTRK1JAK2 | |
| SCHEMBL19466998 | 0.86 | AAK1 (0.50) | AAK1SMPD3PDE10A | |
| SCHEMBL19466997 | 0.86 | AAK1 (0.50) | AAK1SMPD3PDE10A | |
| SCHEMBL19466712 | 0.86 | AAK1 (0.57) | AAK1SMPD3NTRK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677705-A | AAK1 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115677705-A | AAK1 inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | IRAK1, SARS1, IRAK2 | AAK1 4/4885SMPD3 3682/4885NTRK1 1718/4885 |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | IRAK1, SARS1, IRAK2 | AAK1 4/4885SMPD3 3682/4885NTRK1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.